公司問答丨沃森生物:公司主要採用“學術推廣+線上營銷”的銷售模式
格隆匯6月9日丨有投資者在投資者互動平台向沃森生物公司提問:請問貴司沒有自己直營的業務銷售部嗎?官網和社招平台都看不到任何歷史招聘信息。採用的學術推廣模式也都是合作,購買第三方的服務嗎?研發技能和銷售網都不是自己的,請問核心競爭力在哪?沃森生物回覆稱,公司主要採用“學術推廣+線上營銷”的銷售模式,通過構建“商務經理-產品經理-醫學經理”的“鐵三角”管理體系對合作夥伴進行自營化管理,以學術會議、科普活動、媒體宣傳等形式提高公司產品的認知度和認可度。截止到2023年3月31日,公司研發人員共計178人,公司已構建了科學高效的研發項目決策及管理體系,採用自主研發、合作研發與項目引進並重的研發模式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.